This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tonix Pharmaceuticals Receives Health Canada Clearance To Study A Novel Treatment For Fibromyalgia

Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”) including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), announces that the Company will initiate a comparative study on a novel treatment for FM that targets sleep problems associated with chronic pain syndromes. TONIX’s new approach is opiate-free and non-addictive.

Health Canada has provided TONIX with clearance for a comparative pharmacokinetic (“PK”) and bioavailability (“BA”) study of TNX-102, the Company’s novel oral formulation of cyclobenzaprine for the treatment of FM. Health Canada has issued a No Objection Letter to TONIX’s Clinical Trial Application. Cyclobenzaprine is the active ingredient in two U.S. FDA- and Health Canada-approved prescription muscle relaxants that are marketed by other companies.

Seth Lederman, M.D., Chairman and President of TONIX said, “FM patients are desperate to get a good night’s sleep because many have learned that restorative sleep can improve their pain and fatigue. We have designed TNX-102 to work at night after bedtime administration. We expect the results of this PK study will corroborate studies done in animals, and we will use the findings to finalize our commercial formulation for pivotal clinical studies.”

Dr. Lederman also said, “The objective of this study is to compare the PK profile of our proprietary TNX-102 formulation with the PK of a conventional immediate release formulation and the PK of an intravenous injection.”

In addition, Dr. Lederman noted, “Immediate release cyclobenzaprine results in relatively steady blood levels over the course of the day, which is ideal for the treatment of muscle spasms, its approved indication. In our Phase 2a study, bedtime administration of very low dose cyclobenzaprine capsules improved core FM symptoms including pain, tenderness, fatigue and depression. This study also demonstrated that those improvements were correlated with increased nights of restorative sleep. Our goal is to develop a bedtime cyclobenzaprine treatment with more predictable beneficial effects and reduced next-day somnolence compared with the current doses and formulations of cyclobenzaprine.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs